Neurogene Inc., a New York-based company developing a pipeline of gene therapies for rare neurological diseases, has secured a $68.5 million series A financing to support its work. Investors in the adeno-associated virus (AAV)-focused startup included Samsara Biocapital, EcoR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed healthcare investment fund.